{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T22:45:46Z","timestamp":1784673946981,"version":"3.55.0"},"reference-count":15,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2011,5,25]],"date-time":"2011-05-25T00:00:00Z","timestamp":1306281600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Chair's Grant","award":["U10 CA98543 and U10 CA98413"],"award-info":[{"award-number":["U10 CA98543 and U10 CA98413"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2012,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Extramedullary leukemia (EML) is common in pediatric acute myeloid leukemia (AML) and occurs as leukemia cells within the cerebrospinal fluid (CSF) or as a solid tumor (myeloid sarcoma\u2014MS). The effect of MS on survival is unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Patients on CCG protocols 2861, 2891, 2941, and 2961 being treated for AML with intensive\u2010timing chemotherapy were classified for the presence of EML (CSF leukemia, CNS\u2010MS, orbital\u2010MS, or non\u2010CNS MS). CSF leukemia was classified as CNS3 (\n                      <jats:styled-content>&gt;<\/jats:styled-content>\n                      5 WBC in the CSF with blasts) and non\u2010CSF leukemia as CNS1\/2 (&lt;5 WBC in the CSF with or without blasts). Characteristics and outcomes of these patients were compared.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 1,459 total patients, 1,206 (82%) had no EML, 154 (11%) had CSF leukemia, 19 (1%) had CNS\u2010MS, 23 (2%) had orbital\u2010MS, and 57 (4%) had non\u2010CNS MS. The CR rate was significantly higher in patients with orbital\u2010MS and CNS\u2010MS than in those with non\u2010MS and non\u2010CNS MS (96% and 95% vs. 78% and 78%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.034). Patients with orbital\u2010MS and CNS\u2010MS had significantly higher overall survival than patients with non\u2010CNS MS (92% and 73% vs. 38%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001), CNS3 patients (92% and 73% vs. 51,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001), and CNS1\/2 patients (92% and 73% vs. 50%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001). Patients with orbital\u2010MS had a significantly lower relapse rate.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Patients with MS involving orbital and CNS sites had a significantly better survival than patients with non\u2010CNS MS, with CSF leukemia, or with no EML. Pediatr Blood Cancer 2012; 58: 519\u2013524. \u00a9 2011 Wiley Periodicals, Inc.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/pbc.23201","type":"journal-article","created":{"date-parts":[[2011,5,25]],"date-time":"2011-05-25T08:08:21Z","timestamp":1306310901000},"page":"519-524","source":"Crossref","is-referenced-by-count":69,"title":["Superior outcome of pediatric acute myeloid leukemia patients with orbital and CNS myeloid sarcoma: A report from the Children's Oncology Group"],"prefix":"10.1002","volume":"58","author":[{"given":"Donna L.","family":"Johnston","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd A.","family":"Alonzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert B.","family":"Gerbing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beverly J.","family":"Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William G.","family":"Woods","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,5,25]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-209262"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-200310000-00004"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403131"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22511"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.8.1448"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.12.4979.bloodjournal87124979"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.04.016"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-04-084293"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402449"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-911X(199809)31:3<144::AID-MPO3>3.0.CO;2-B"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.20824"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190290012056"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.4.690"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2004.01.006"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(20000415)88:8<1939::AID-CNCR24>3.0.CO;2-Z"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.23201","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.23201","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.23201","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T08:33:08Z","timestamp":1697617988000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.23201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5,25]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["10.1002\/pbc.23201"],"URL":"https:\/\/doi.org\/10.1002\/pbc.23201","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.11341957.12858055","asserted-by":"object"}]},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5,25]]}}}